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Eur J Vasc Endovasc Surg (2011) 42, S114eS115CommentaryT.F. O’Donnell Jr.Vein Center at Tufts Medical Center and Dedham Medical Associates, Boston, MA, USAIn this paper, Lurie et al. reported the two year follow-up
data1 from the EVOLVeS randomized controlled trial (RCT)2
and offered unique information on the intermediate clin-
ical and functional results following radiofrequency ablation
(RFA) or ligation and stripping (L&S) of the great saphenous
vein (GSV). Most importantly, the incidence and causes of
recurrent varicose veins were detailed following RFA. Lur-
ie’s initial report in 2003 from the EVOLVeS study was the
first moderately large and only multicentre RCT to address
early objective clinical, Quality of Life (QoL) and duplex
findings following endovenous ablation (EVA), either by
radiofrequency (RFA) or laser (EVLA).2 Enthusiasm for this
minimally invasive approach led to a progressive increase in
the annual number of saphenous procedures to over 300,000
cases world-wide and a decreased volume of the more
invasive L&S procedures.3 Yet, prior to Lurie’s follow-up
study, physicians and patients were unsure if they were
trading a “kinder and gentler” technique with fewer peri-
procedural side effects (less pain, earlier return to work)
for a higher rate of recurrent varicose veins following EVA.
Evidentiary strength from the study has been related to
appropriate elements of study design as well as patient-
relevant outcome measures.4 One of the unique features of
this trial was that it included a longitudinal and objective
clinical outcome measure, the VCSS (Venous Clinical
Severity Score)5 as well as a validated disease-specific
outcome assessment of QOL, the CIVIQ2 (Chronic Venous
Insufficiency Questionnaire).6 Finally, through sequential
clinical and duplex assessment, important data was pre-
sented on the incidence and potential causes of recurrent
varicose veins (Table 1).
At two years of follow-up, 80% of the limbs in both
groups were available for evaluation. The early advantage
of the RFA group in VCSS over the L&S group had dis-
appeared, but both groups showed a significantDOI of original article: 10.1016/j.ejvs.2004.09.019.
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report, superior CIVIQ2 scores were observed at 72 h
through one week for the RFA group, but at one and two
years of follow-up, the significant advantage in QoL for RFA
reappeared, which is a unique finding in this study versus
other similar RCTs. Finally, at two years of follow-up, three
patients in the RFA group had patent segments with reflux
by duplex, while an equal number of the L&S group had
incompetent GSV remnants (Table 1).
Several investigators have theorized that with EVA the
avoidance of an inguinal incision and resection of the prox-
imal GSV and the resultant saphenous stumpmight lower the
possibility of neovascularization at the sapheno-femoral
junction as a cause of recurrence.7 The sole instance of
neovascularization in the RFA group was found in a patient
with an early technical failure and a resultant patent and
incompetent GSV segment (2%). By contrast, neovasculari-
zation developed in four (14%) of the L&S group (pZ ns). The
cumulative rate of recurrent varicosities was numerically
greater in the L&S group (20.9%) versus the RFA group (14.3%)
at 2 years, but did not reach statistical significance. Irre-
spective of the specific treatment group, the presence of
a patent segment of GSV increased the likelihood of
recurrence.
Lurie’s original report on the intermediate incidence
and cause of recurrent varicosities following EVA has been
confirmed by four similar RCTs (1 RFA and 3 EVLA) which
were published five years later (Table 1). No difference in
the rate of recurrent varicose veins was observed between
the EVA and L&S arms across all the studies, while the
incidence of neovascularization was limited by the low
event rate. The number of patent segments following RFA
in Lurie’s study may be influenced by the use of the older
continuous withdrawal Closure-Plus device (85e90 C)
which is no longer manufactured and produces lower J/
cm. than the newer segmental Closure Fast device (120 C
for 20 seconds-70 J/cm per segment).
In summary; Lurie’s high quality RCT showed that the
intermediate incidence of recurrent varicose veins andd by Elsevier Ltd. All rights reserved.
Table 1 Comparison of recurrent varicose veins following eva and L&S number and (percent).
Study/(year) F.U.
(years)
Limbs
(number)
Patent/reflux
Segs.
Rec. VVs
clinical
Neo-vasc
Lurie1
(2005)
RFA
L & S
2
2
36
29
3 (8)
3(10)
5 (14.3)
6 (20.9)
1 (3)
4 (14)
Perala8
(2005)
RFA
L & S
3
3
15
13
1 (7)
1(8)
5 (33)
2 (15)
1 (8)
1 (7)
Pronk9
(2010)
EVLA
L & S
1
1
49
56
5 (10)
5 (9)
3 (6)
3 (5.4)
e
Christenson10
(2010)
EVLA
L & S
2
2
95
99
7 (8)
0
6 (6)
1 (1)
e
Rasmussen11
(2010)
EVLA
L & S
2
2
69
68
4 (6)
9 (14)
18 (26)
25 (37)
2 (3)
3 (5)
El Kaffas12
(2011)
RFA
L & S
2
2
81
82
e 12 (13.3)
9 (10)
e
F.U. Z Follow-up (years); Patent Segs. Z Patent GSV segments on duplex; Rec VVs Z Recurrent varicosities; Neo-
Vasc Z Neovascularization; AASV Z Anterior accessory saphenous vein.
Commentary S115patent segments with reflux in RFA were comparable to
ligation and stripping. Any vascular procedure has to be
judged on its durability and efficacy and Lurie’s study
provided a two year validation of RFA, while maintaining
both an improved clinical and functional outcome.References
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